//
L. Mitchell
D. Roeshammar
F. Huang
M. Albisetti
L. Brandao
L. Bomgaars
E. Chalmers
J. Halton
M. Luciani
D. Joseph
I. Tartakovsky
S. Gropper
P. Reilly
M. Brueckmann
J. Stangier
Pharmetheus,Uppsala,Sweden
Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, United States
University Children's Hospital, Hematology Department, Zürich, Switzerland
Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Texas Children's Cancer Center, Baylor College of Medicine, Department of Pediatrics, Houston, United States
Royal Hospital for Sick Children, Glasgow, United Kingdom
Children's Hospital of Eastern Ontario and University of Ottawa, Ottawa, ON, Canada,
Pediatric Hospital Bambino Gesù, Pediatric Hematology/Oncology, Rome, Italy
Therapeutic Area Cardiovascular Medicine, Boehringer Ingelheim International GmbH, Ingelheim, Germany
Therapeutic Area Cardiovascular Medicine, Boehringer Ingelheim International GmbH, Ingelheim, Germany
Therapeutic Area Cardiovascular Medicine, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, United States
Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany
Canada
Sweden
United States
Switzerland
United Kingdom
Italy
Germany
N/A
Pulmonary/Respiratory Diseases
Cardiovascular (CVS)
Blood/haematological Diseases
Venous thrombosis
N/A
Pradax
N/A
Pharmacokinetics
Pharmacodynamics
II
N/A
N/A
N/A